Cargando…

Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study

BACKGROUND: Enhanced innate immune response is detected in autopsy studies of Parkinson’s disease (PD) but the role of microglia in early pathophysiology is unclear. While the translocator protein 18 kDa (TSPO) that marks glial activation may be high in PD, TSPO expression is not limited to microgli...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Kelly A., Du, Yong, Coughlin, Jennifer M., Horti, Andrew G., Jenkins, Katelyn, Spiro, Ergi, Motley, Chelsie S., Dannals, Robert F., Pomper, Martin G., Dawson, Ted M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312881/
https://www.ncbi.nlm.nih.gov/pubmed/37398476
http://dx.doi.org/10.1101/2023.05.28.23290647
_version_ 1785067002228899840
author Mills, Kelly A.
Du, Yong
Coughlin, Jennifer M.
Horti, Andrew G.
Jenkins, Katelyn
Spiro, Ergi
Motley, Chelsie S.
Dannals, Robert F.
Pomper, Martin G.
Dawson, Ted M.
author_facet Mills, Kelly A.
Du, Yong
Coughlin, Jennifer M.
Horti, Andrew G.
Jenkins, Katelyn
Spiro, Ergi
Motley, Chelsie S.
Dannals, Robert F.
Pomper, Martin G.
Dawson, Ted M.
author_sort Mills, Kelly A.
collection PubMed
description BACKGROUND: Enhanced innate immune response is detected in autopsy studies of Parkinson’s disease (PD) but the role of microglia in early pathophysiology is unclear. While the translocator protein 18 kDa (TSPO) that marks glial activation may be high in PD, TSPO expression is not limited to microglia, and ligand binding affinity for newer generation radiotracers for imaging TSPO with PET varies across individuals due to a common single nucleotide polymorphism in TSPO. Imaging the colony stimulating factor 1 receptor (CSF1R) with [(11)C]CPPC PET offers an opportunity to image a complementary in vivo marker of microglial number and/or activity in early PD. OBJECTIVE: To determine whether the binding of [(11)C]CPPC differs across the brains of healthy controls and patients with early PD, and to test for correlation between binding and disease severity in early PD. METHODS: Healthy controls and persons with PD of ≤2 years disease duration and Hoehn & Yahr <2.5 were enrolled. Each participant underwent motor and cognitive ratings, and then completed [(11)C]CPPC dynamic PET with serial arterial blood sampling. The total volume of tissue distribution (V(T)) in PD-relevant regions of interest was compared between groups (healthy controls, mild versus moderate PD) based on disability from motor symptoms (MDS-UPDRS Part II) and also was regressed with MDS-UPDRS Part II as a continuous measure. Correlations between V(T) and cognitive measures were explored. RESULTS: PET imaging showed higher [(11)C]CPPC binding in multiple regions in patients with more motor disability than those with less motor disability and compared to healthy controls. In patients with mild cognitive impairment (PD-MCI), higher CSF1R binding by [(11)C]CPPC was associated with worse cognitive function on Montreal Cognitive Assessment (MoCA). This inverse correlation was also found between [(11)C]CPPC V(T) and verbal fluency across the entire PD cohort. CONCLUSIONS: Even at early stages of disease, [(11)C]CPPC that binds the CSF1R, a direct marker of microglial density and activation, correlates with motor disability in PD and cognitive function.
format Online
Article
Text
id pubmed-10312881
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-103128812023-07-01 Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study Mills, Kelly A. Du, Yong Coughlin, Jennifer M. Horti, Andrew G. Jenkins, Katelyn Spiro, Ergi Motley, Chelsie S. Dannals, Robert F. Pomper, Martin G. Dawson, Ted M. medRxiv Article BACKGROUND: Enhanced innate immune response is detected in autopsy studies of Parkinson’s disease (PD) but the role of microglia in early pathophysiology is unclear. While the translocator protein 18 kDa (TSPO) that marks glial activation may be high in PD, TSPO expression is not limited to microglia, and ligand binding affinity for newer generation radiotracers for imaging TSPO with PET varies across individuals due to a common single nucleotide polymorphism in TSPO. Imaging the colony stimulating factor 1 receptor (CSF1R) with [(11)C]CPPC PET offers an opportunity to image a complementary in vivo marker of microglial number and/or activity in early PD. OBJECTIVE: To determine whether the binding of [(11)C]CPPC differs across the brains of healthy controls and patients with early PD, and to test for correlation between binding and disease severity in early PD. METHODS: Healthy controls and persons with PD of ≤2 years disease duration and Hoehn & Yahr <2.5 were enrolled. Each participant underwent motor and cognitive ratings, and then completed [(11)C]CPPC dynamic PET with serial arterial blood sampling. The total volume of tissue distribution (V(T)) in PD-relevant regions of interest was compared between groups (healthy controls, mild versus moderate PD) based on disability from motor symptoms (MDS-UPDRS Part II) and also was regressed with MDS-UPDRS Part II as a continuous measure. Correlations between V(T) and cognitive measures were explored. RESULTS: PET imaging showed higher [(11)C]CPPC binding in multiple regions in patients with more motor disability than those with less motor disability and compared to healthy controls. In patients with mild cognitive impairment (PD-MCI), higher CSF1R binding by [(11)C]CPPC was associated with worse cognitive function on Montreal Cognitive Assessment (MoCA). This inverse correlation was also found between [(11)C]CPPC V(T) and verbal fluency across the entire PD cohort. CONCLUSIONS: Even at early stages of disease, [(11)C]CPPC that binds the CSF1R, a direct marker of microglial density and activation, correlates with motor disability in PD and cognitive function. Cold Spring Harbor Laboratory 2023-06-03 /pmc/articles/PMC10312881/ /pubmed/37398476 http://dx.doi.org/10.1101/2023.05.28.23290647 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Mills, Kelly A.
Du, Yong
Coughlin, Jennifer M.
Horti, Andrew G.
Jenkins, Katelyn
Spiro, Ergi
Motley, Chelsie S.
Dannals, Robert F.
Pomper, Martin G.
Dawson, Ted M.
Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study
title Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study
title_full Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study
title_fullStr Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study
title_full_unstemmed Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study
title_short Microglial CSF1R radioligand [(11)C]CPPC as a marker of disease severity in early Parkinson’s disease: a pilot study
title_sort microglial csf1r radioligand [(11)c]cppc as a marker of disease severity in early parkinson’s disease: a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312881/
https://www.ncbi.nlm.nih.gov/pubmed/37398476
http://dx.doi.org/10.1101/2023.05.28.23290647
work_keys_str_mv AT millskellya microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT duyong microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT coughlinjenniferm microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT hortiandrewg microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT jenkinskatelyn microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT spiroergi microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT motleychelsies microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT dannalsrobertf microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT pompermarting microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy
AT dawsontedm microglialcsf1rradioligand11ccppcasamarkerofdiseaseseverityinearlyparkinsonsdiseaseapilotstudy